A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Clinical trial NCT04625270 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04625270
Sponsor: Verastem, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Low Grade Ovarian Serous Adenocarcinoma Ovarian Cancer

Start date: 2020-12-21
Primary completion: 2024-11-15
Enrollment: 225

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.